Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Takashi Nomizo"'
Autor:
Hiroshi Yoshida, Hiroaki Ozasa, Kentaro Hashimoto, Yusuke Shima, Keiichiro Suminaga, Hitomi Ajimizu, Takashi Nomizo, Hironori Yoshida, Masahiro Yoshioka, Masashi Kanai, Takehito Shukuya, Manabu Muto, Toyohiro Hirai
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 14, Iss , Pp 100286- (2024)
Among cases of non-small cell lung cancer (NSCLC) with EGFR mutations, NSCLC with deletions in EGFR exon 19 or 21 L858R account for 85 %. Frequency of NSCLC with minor mutations in EGFR is about 9 %, whilst EGFR exon 20 insertion mutation account for
Externí odkaz:
https://doaj.org/article/9c163bc24b6e4a9181dc97cc3c256896
Autor:
Hitomi Ajimizu, Hiroaki Ozasa, Susumu Sato, Tomoko Funazo, Yuichi Sakamori, Takashi Nomizo, Kiyomitsu Kuninaga, Tatsuya Ogimoto, Kazutaka Hosoya, Masatoshi Yamazoe, Takahiro Tsuji, Hironori Yoshida, Ryo Itotani, Kentaro Ueno, Young Hak Kim, Shigeo Muro, Toyohiro Hirai
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Chronic obstructive pulmonary disease (COPD) may coexist with lung cancer, but the impact on prognosis is uncertain. Moreover, it is unclear whether pharmacological treatment for COPD improves the patient’s prognosis. We retrospectively in
Externí odkaz:
https://doaj.org/article/f3c791af74a046499c35180097eeba07
Autor:
Hitomi Ajimizu, Hiroaki Ozasa, Susumu Sato, Tomoko Funazo, Yuichi Sakamori, Takashi Nomizo, Kiyomitsu Kuninaga, Tatsuya Ogimoto, Kazutaka Hosoya, Masatoshi Yamazoe, Takahiro Tsuji, Hironori Yoshida, Ryo Itotani, Kentaro Ueno, Young Hak Kim, Shigeo Muro, Toyohiro Hirai
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/54a067459b054ee180ce6a077620ee5a
Autor:
Koichi Hasegawa, Ayano Toriyama, Takashi Nomizo, Hiroko Fukata, Kenichi Goto, Yasukiyo Nakamura, Tatsuo Hamada, Naoki Kanda, Hideo Kita
Publikováno v:
Clinical Case Reports, Vol 8, Iss 12, Pp 3327-3331 (2020)
Abstract Pleural empyema secondary to pancreaticopleural fistula can be caused by ascending infection of enteric organisms from infected pancreatic pseudocysts. This unique route of infection should be noted for appropriate empirical antibiotic thera
Externí odkaz:
https://doaj.org/article/ed24e056dccd40d192273a2c96befebb
Autor:
Takahiro Tsuji, Hiroaki Ozasa, Wataru Aoki, Shunsuke Aburaya, Tomoko Yamamoto Funazo, Koh Furugaki, Yasushi Yoshimura, Masatoshi Yamazoe, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo, Hironori Yoshida, Yuichi Sakamori, Hiroaki Wake, Mitsuyoshi Ueda, Young Hak Kim, Toyohiro Hirai
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-16 (2020)
Relapse is a limitation for the efficacy of the anaplastic lymphoma kinase (ALK)-inhibitor alectinib in ALK-rearranged lung cancer. Here, the authors show that YAP1 activation upon alectinib treatment leads to therapy resistance and that inhibiting b
Externí odkaz:
https://doaj.org/article/3f80ddddea7640be87705e31f5e46a2a
Autor:
Young Hak Kim, Toyohiro Hirai, Mitsuyoshi Ueda, Yuichi Sakamori, Hiroki Nagai, Yoshitaka Yagi, Hironori Yoshida, Koichi Hasegawa, Kiyoshi Uemasu, Takashi Nomizo, Yuto Yasuda, Ryoko Okutani, Hitomi Ajimizu, Yasushi Yoshimura, Koh Furugaki, Tomoko Funazo, Shunsuke Aburaya, Wataru Aoki, Hiroaki Ozasa, Takahiro Tsuji
Fig. S1. Supplementary data for Fig. 1 Fig. S2. Supplementary drug sensitivity data to ALK inhibitors in KTOR1 and KTOR1-RE. Fig. S3. Supplementary results of the phosphoproteome analysis Fig. S4. Saracatinib sensitized KTOR1-RE cells to crizotinib F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5f8b92c4e090d208d1fd9cf32555131
https://doi.org/10.1158/1541-7786.22515762
https://doi.org/10.1158/1541-7786.22515762
Autor:
Young Hak Kim, Toyohiro Hirai, Mitsuyoshi Ueda, Yuichi Sakamori, Hiroki Nagai, Yoshitaka Yagi, Hironori Yoshida, Koichi Hasegawa, Kiyoshi Uemasu, Takashi Nomizo, Yuto Yasuda, Ryoko Okutani, Hitomi Ajimizu, Yasushi Yoshimura, Koh Furugaki, Tomoko Funazo, Shunsuke Aburaya, Wataru Aoki, Hiroaki Ozasa, Takahiro Tsuji
Supplementary Figure S1-S6 and Table S1-S3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5281c8717743da816c7fd5fb10b85788
https://doi.org/10.1158/1541-7786.22515759
https://doi.org/10.1158/1541-7786.22515759
Autor:
Toyohiro Hirai, Young Hak Kim, Hironori Yoshida, Yuichi Sakamori, Takashi Nomizo, Yuto Yasuda, Hitomi Ajimizu, Tetsuya Oguri, Yasushi Yoshimura, Koh Furugaki, Hiroaki Ozasa, Takahiro Tsuji, Tomoko Funazo
Alectinib is used as a first-line treatment for anaplastic lymphoma kinase (ALK)-rearranged non–small cell lung cancer (NSCLC). Whereas other ALK inhibitors have been reported to be involved in resistance to ATP-binding cassette (ABC) transporters,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac7a854b2d31d7a986a69421d9175fec
https://doi.org/10.1158/1535-7163.c.6542827
https://doi.org/10.1158/1535-7163.c.6542827
Autor:
Toyohiro Hirai, Young Hak Kim, Hironori Yoshida, Yuichi Sakamori, Takashi Nomizo, Yuto Yasuda, Hitomi Ajimizu, Tetsuya Oguri, Yasushi Yoshimura, Koh Furugaki, Hiroaki Ozasa, Takahiro Tsuji, Tomoko Funazo
Figure S1. Schematic representation of the ABCC11 expression vector. Figure S2. Sequence analysis of the tyrosine kinase coding region of anaplastic lymphoma kinase (ALK). Figure S3. Cell viability assay of alectinib in H2228 and H2228-AR1S cells und
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2799a23a2f7650adc680988fed098774
https://doi.org/10.1158/1535-7163.22520917.v1
https://doi.org/10.1158/1535-7163.22520917.v1
Autor:
Young Hak Kim, Toyohiro Hirai, Mitsuyoshi Ueda, Yuichi Sakamori, Hiroki Nagai, Yoshitaka Yagi, Hironori Yoshida, Koichi Hasegawa, Kiyoshi Uemasu, Takashi Nomizo, Yuto Yasuda, Ryoko Okutani, Hitomi Ajimizu, Yasushi Yoshimura, Koh Furugaki, Tomoko Funazo, Shunsuke Aburaya, Wataru Aoki, Hiroaki Ozasa, Takahiro Tsuji
The mechanisms responsible for the development of resistance to alectinib, a second-generation anaplastic lymphoma kinase (ALK) inhibitor, are still unclear, and few cell lines are currently available for investigating ALK-rearranged lung cancer. To
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::19239d85597906a945aad8a994cd19ac
https://doi.org/10.1158/1541-7786.c.6541176
https://doi.org/10.1158/1541-7786.c.6541176